Leiden, Amsterdam, 1st of October  2025 – Abilia, a subsidiary of MedCap AB (publ) and part of Business Area Assistive Tech, has signed an agreement to acquire Holland Capital’s portfolio company LivAssured B.V.

Holland Capital and LivAssured

LivAssured was founded from a Dutch research consortium with the mission to develop NightWatch, a clinically validated seizure monitor designed to detect severe epileptic seizures during sleep. Since its market introduction in 2018, NightWatch has had a major positive impact across the epilepsy community in Europe, supporting patients, caregivers, and healthcare professionals with reliable detection and real-time alerts. Today, the system is used by thousands of families and care institutions and has proven its value in both daily life and clinical practice. Holland Capital has actively supported LivAssured in both operational and strategic development since becoming a shareholder in 2018.

Jeroen van den Hout, Managing Director of LivAssured, comments on the acquisition: “We are immensely grateful for the years of support from Holland Capital. They have been a true sparring partner, not only on a strategic level but also at times on operational challenges. Their involvement has been invaluable in helping us grow and prepare for this exciting new phase with Abilia.”

Sterre Witteveen, Investment Manager at Holland Capital and Supervisory Board Member at LivAssured, adds: “We are very proud of the entire LivAssured team and what they have achieved with NightWatch. It is rewarding to see how their dedication has led to a product that can now, under the wings of Abilia, help epilepsy patients and their caregivers on a global scale. We are excited for the journey ahead and confident that this partnership will maximize NightWatch’s impact.”

About Abilia

Abilia, headquartered in Sweden, has decades of experience developing and providing assistive technology in areas such as cognition, communication, environmental control, and alarms. Abilia’s solutions are built on evidence and close collaboration with healthcare professionals, with the goal of empowering people with special needs to live more independent lives. The acquisition of LivAssured significantly strengthens Abilia’s existing offering in seizure monitoring and creates new opportunities to expand internationally. With Abilia’s established market presence and expertise, LivAssured will be able to accelerate its growth and ensure more people with epilepsy and their caregivers benefit from reliable seizure detection.

About Holland Capital

Holland Capital has been responsibly and successfully  investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare and Technology sector.